Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s share price traded up 6.8% on Tuesday . The stock traded as high as $3.40 and last traded at $3.35. 228,018 shares traded hands during trading, a decline of 73% from the average session volume of 845,629 shares. The stock had previously closed at $3.14.
Analyst Upgrades and Downgrades
Separately, Cormark upgraded shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Strong Buy".
Get Our Latest Stock Report on CURLF
Curaleaf Stock Performance
The company's 50 day moving average is $2.61 and its 200-day moving average is $1.50. The company has a market capitalization of $2.17 billion, a P/E ratio of -10.09 and a beta of 0.71. The company has a current ratio of 1.47, a quick ratio of 0.70 and a debt-to-equity ratio of 1.00.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. Equities analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 EPS for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.